Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Finasteride - Merck & Co.

Drug Profile

Finasteride - Merck & Co.

Alternative Names: Anatine; Andozac; Avertex; Chibro-Proscar; Eutiz; Finasterin; Finastid; Jacarin; MK-0906; MK-906; Nasteril; Penester; Pro-Cure; Prodel; Propecia; Proscar; Prostene; Prosterid; Prostide; Tealep; YM-152

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Class Androstenes; Antiacnes; Antiandrogens; Antineoplastics; Azasteroids; Skin disorder therapies; Small molecules
  • Mechanism of Action Cholestenone 5-alpha reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alopecia; Benign prostatic hyperplasia
  • No development reported Prostate cancer

Most Recent Events

  • 27 May 2015 No recent reports of development identified - Phase-III for Prostate cancer (Prevention) in Canada and USA (PO)
  • 05 Feb 2014 MSD Korea and Hanmi Pharmaceutical agree to co-promote finasteride in South Korea for Alopecia and Benign prostatic hyperplasia
  • 01 Nov 2013 Merck discontinues the phase III trial in Benign prostatic hyperplasia in China (NCT01534351)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top